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Background: A disproportionate amount of body fat within the abdominal cavity, otherwise known as visceral
obesity, best predicts the negative health outcomes associated with high levels body fat. Growing evidence
suggests that repeated activation of the stress response can favor visceral fat deposition and that visceral obesity
may induce low-grade, systemic inflammation which is etiologically linked to the pathogenesis of obesity related
diseases such as cardiovascular disease and type 2 diabetes. While the obesity epidemic has fueled considerable
interest in these obesity-related inflammatory diseases, surprisingly little research is currently focused on
understanding the functions of inflammatory proteins in healthy, non-obese white adipose tissue (WAT) and their
possible role in modulating stress-induced shifts in body fat distribution.
Hypothesis: The current review presents evidence in support the novel hypothesis that stress-evoked interleukin-1
beta (IL-1β) signaling within subcutaneous adipose tissue, when repeatedly induced, contributes toward the
development of visceral obesity. It is suggested that because acute stressor exposure differentially increases IL-1β
levels within subcutaneous adipose relative to visceral adipose tissue in otherwise healthy, non-obese rats, repeated
induction of this response may impair the ability of subcutaneous adipose tissue to uptake energy substrates,
synthesize and retain triglycerides, and/or adapt to positive energy balance via hyperplasia. Consequently,
circulating energy substrates may be disproportionately shunted to visceral adipose tissue for storage, thus driving
the development of visceral obesity.
Conclusions: This review establishes the following key points: 1) body fat distribution outweighs the importance of
total body fat when predicting obesity-related disease risk; 2) repeated exposure to stress can drive the
development of visceral obesity independent of changes in body weight; 3) because of the heterogeneity of WAT
composition and function, an accurate understanding of WAT responses requires sampling multiple WAT depots; 4)
acute, non-pathogenic stressor exposure increases WAT IL-1β concentrations in a depot specific manner suggesting
an adaptive, metabolic role for this cytokine; however, when repeated, stress-induced IL-1β in non-visceral WAT may
result in functional impairments that drive the development of stress-induced visceral obesity.Background
Advances in our understanding of the etiology of weight
gain and the regulation of energy homeostasis have greatly
contributed toward the widespread efforts to combat obes-
ity. While it has become increasingly apparent that dispro-
portionate amounts of visceral white adipose tissue
(WAT) and a low-grade inflammatory state contribute to
the pathogenesis of obesity [1-5] the mechanisms that
regulate the distribution of body fat and the functions of
inflammatory proteins in healthy, non-obese WAT remain* Correspondence: fleshner@colorado.edu
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distribution, and reproduction in any mediumunclear. Interestingly, stressor exposure and immunity
have both been found to impact metabolism and to be
linked to the development of visceral obesity [5-13]. Des-
pite this evidence, little attention has been paid to the
metabolic effects of cytokines in healthy, non-obese adi-
pose tissue or the potential effects of repeated stress on
WAT function. Herein we present new data that inflam-
matory proteins are elevated by non-pathogenic stress
resulting in depot-specific shifts in the local cytokine mi-
lieu of non-obese WAT [14] supporting the hypothesis
that the immune system may play a role in the regulation
of body fat distribution through depot specific immune-
metabolic interactions. This review presents evidence thatCentral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Factors associated with the development of
visceral obesity
Factor Association Reference
Genetics Ethnicity, hypothalamic genetic
disorders, etc.
[28-32]
Age " Age!" WC (Age> 60!" WC) [33,34]
Sex Male WC> Female WC [33]
Physical Activity Status " Physical Activity Status!# WC [35,36]
Dietary Composition " Fat/Fructose content!" WHR [37-39]
Smoking " Smoking!" WHR [8,40]
Alcohol Consumption " Alcohol consumption!" WHR [8,41]
Socio-Economic Status # Socio-Economic Status!" WHR [8,42]
Stress-related Mood " Depression/Anxiety!" WHR [8,43]
Disorders
Abbreviations: WC, waist-circumference; WHR, waist-to-hip circumference ratio.
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ment of visceral obesity and that stress-induced cytokine
production may play an integral role in this maladaptive
effect. We begin by arguing that body fat distribution out-
weighs the importance of total body fat followed by a dis-
cussion of stress-induced visceral obesity. We then present
data in support of the hypothesis that acute, stress-
induced shifts in non-visceral WAT cytokines serve adap-
tive functions that become maladaptive when repeated.
More specifically, we hypothesize that stress-evoked eleva-
tions impair the ability of non-visceral WAT to uptake,
resynthesize and retain lipids, and/or to expand in the face
of positive energy balance and that these cytokine-driven
impairments consequently contribute to the development
of visceral obesity.
Body fat distribution and obesity-related disease risk
Obesity, or excess WAT, affects more than 33 % of the
American population today [15] but is excess body fat
really bad for you? Although studies demonstrate that
chronic non-communicable diseases such as type 2 dia-
betes and cardiovascular disease coincide with the rise in
obesity not all forms of obesity are associated with meta-
bolic syndrome and chronic-disease development [16-
19]. What’s more, current epidemiological research sug-
gests that the way in which WAT is distributed through-
out the body is a better predictor of obesity-related
disease risk than total body fat mass [1-4]. Numerous
studies have demonstrated that obesity-related health
risk in humans is strongly correlated with an increased
ratio of visceral fat mass relative to non-visceral fat mass
(i.e. increased anthropometric measures such as waist-
circumference and waist-to- hip ratios) suggesting that
this is a maladaptive body fat distribution reflective of
visceral obesity [20-22]. A worldwide case–control study
done by Yusuf et al. (2005), for example, demonstrated
that the waist-to-hip circumference ratio - an indirect es-
timate of visceral obesity - far exceeds Body Mass Index
(BMI = body weight (kg)/height (m)2) in its association
with myocardial infarction risk [1]. Evidence also con-
versely demonstrates that a reduced ratio of visceral fat
mass relative to non-visceral fat mass is correlated with
reduced disease risk [23,24]. Furthermore, while a dis-
proportionate accumulation of visceral WAT is corre-
lated with chronic low-grade inflammation and
pathogenesis, the opposite appears to be true for dispro-
portionate amounts of non-visceral WAT [3,25-27].
Manolopoulos et al. (2010) recently reviewed the pro-
tective properties of gluteofemoral fat in humans (i.e.
WAT stored in the thighs and hips) suggesting that these
non-visceral, subcutaneous fat depots act as a ‘metabolic
sink’ for the daily influx and long term storage of dietary
lipids [26]. In other words, to the degree it can effectively
uptake circulating energy substrates such as lipidsand glucose, resynthesize and retain triglycerides (the
storage form of energy in WAT) and expand in response
to positive energy balance, non-visceral WAT - or sub-
cutaneous WAT in humans - is thought to protect
against the development of visceral obesity. Collectively
these studies corroborate epidemiological evidence fur-
ther demonstrating that body fat distribution outweighs
the importance of total body fat when predicting obesity-
related disease risk. What factors, then, lead to the dis-
proportionate accumulation of visceral body fat?
Visceral obesity: the stress hypothesis
As with any long-term physiological response, the devel-
opment of visceral obesity occurs as a result of complex
interactions between genetic and environmental factors
[28]. A summary of factors known to affect body fat dis-
tribution is presented in Table 1.
Notably, life stress, or the real or imagined experience
of an adverse event [44] negatively impacts nearly all of
the factors associated with the development of visceral
obesity (Table 1). For example, high levels of life stress are
linked to poor dietary habits [45], addictive behaviors such
as smoking and alcohol consumption [46-48], a low
socio-economic status [8], and an increased prevalence of
mood disorders such as depression and anxiety [49].
The notion that visceral obesity may be a physiological
adaptation to chronic or repeated stress first came to
fruition in the early 1980s through the clinical research
of Per Björntorp [50,51]. Along with collaborator Roland
Rosmond, Björntorp observed that individuals with low
economic status who were repeatedly subjected to psy-
chosocial and economic stressors developed both pertur-
bations in hypothalamic-pituitary-adrenal (HPA) axis
function and increased visceral adiposity [42,50]. Björn-
torp and Rosmond accordingly hypothesized that dispro-
portionate gains in visceral fat mass may be due to an
increase in HPA axis activity induced by repeated
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foundation for stress-induced visceral obesity by demon-
strating that: (a) the HPA axis is finely tuned to and in
connection with an individual’s real or perceived envir-
onment [9,52]; (b) frequent, repeated activation of the
HPA axis often leads to dysregulated HPA activity as evi-
dence by low diurnal variability with elevated and/or sus-
tained glucocorticoid responses to an acute stressor and/
or a dampened negative feedback response stress follow-
ing an injection of dexamethasone (a glucocorticoid
agonist) [9,53,54]; and (c) dysregulation of the HPA axis
is positively correlated with visceral obesity [9].
Additional support for the stress hypothesis can be
found in epidemiological studies demonstrating a correl-
ation between waist-to-hip circumference ratio, low
socio-economic status (i.e. low income and/or low edu-
cation level) [15,55] and job stress [42,56]. Elevated
waist-to-hip circumference ratios are also associated with
stress-related mood disorders such as anxiety and de-
pression [57]. Potential causative factors in the observed
association between stress and visceral obesity include
increased glucocorticoid activity in WAT depots [58], ex-
cessive vulnerability to the external environment due to
the sustained and uncontrollable stress of poverty and/or
threatening social pressures [59-61], and - due to their
low cost and high palatability - increased consumption
of foods that are high in fat and/or glycemic load and of
a low nutritional value [45,60,61]. In spite of these cor-
relative observations the pathogenic mechanisms linking
stress with a central redistribution of body fat remain
unclear. This is likely due to the fact that accurate as-
sessment of visceral fat mass in humans can only be
done through scan-based systems such as computed
tomography and magnetic resonance imaging. Because
they allow for the precise quantification of visceral fat
mass through dissection, however, animal models serve
as effective tools for investigating stress-induced visceral
obesity [62,63].
Animal models of chronic stress include repeated ex-
posure to physical restraint [64], conditioned fear [65],
foot or tail-shock [66], novel or loud noises [64], social
stress [67,68], or a combination of multiple stressors. In
support of the stress hypothesis, animals exposed to
chronic social stress often display maladaptive changes
in their body fat distribution though this is rarely
detected in the face of body weight gain [63,64]. Con-
trary to the high degree of body weight variability
reported in chronically stressed humans [69] animals
normally reduce their total body weight in response to
repeated stressor exposure because they eat less in com-
bination with the metabolic demands of the stress re-
sponse [62,63,67]. Although these data superficially
contradict the stress hypothesis, upon proper quantifica-
tion of body fat distribution, chronically stressed animalsoften demonstrate a maladaptive shift in the distribution
of their body fat stores irrespective of changes in body
weight [67,70-74]. The development of visceral obesity
may therefore not always be detected in animals exposed
to repeated stress because a) visceral versus non-visceral
fat depots remain unclearly defined; b) body fat distribu-
tion is assessed inconsistently or improperly and/or c)
the lack of standardization with regard to the palatability
of the diet. These inconsistent results highlight the im-
portance of properly assessing and defining body fat dis-
tribution - not just total adiposity or individual fat pad
weights - when evaluating the effects of stressor expos-
ure on the development of visceral obesity.
Clarifying the assessment of body fat distribution: visceral
versus non-visceral WAT
Although it is widely accepted that body composition is
defined as the mass of total body fat relative to total
body weight, the definition of body fat distribution
remains unclear in the literature. Most agree that it is
quantified as the ratio of visceral fat mass relative to
non-visceral fat mass or total body fat mass [29]; the am-
biguities lay within the conflicting opinions about the
depots that constitute visceral WAT [58].
Based upon their anatomical location, WAT depots are
heterogeneous in their innervation pattern [75-77], com-
position [78-81] and function [81-83]. The predominant
storage locations of WAT in mammals are the subcuta-
neous depots located between the epidermis and muscle
and the intra-abdominal depots found within the peri-
toneal cavity [29]. For the intra-abdominal depots -
which include the omental, mesenteric, gonadal, retro-
peritoneal and perirenal depots - further distinctions are
made in reference to the circulatory system into which
they drain [84]. Explicitly, the omental and mesenteric
depots drain directly into the portal venous system while
the gonadal, retroperitoneal, and perirenal depots drain
into the general venous circulation [84,85]. Because of
this quintessential distinction the omental and mesen-
teric depots are considered to be true visceral WAT; the
subcutaneous depots and remaining intra-abdominal
depots (gonadal, retroperitoneal, perirenal) thus consti-
tute non-visceral WAT [84-86]. When visceral WAT
mass is clearly defined as portal draining WAT, body fat
distribution emerges as a quantifiable ratio of visceral
WAT mass, or the weight of the omental and mesenteric
depots, relative to non-visceral WAT mass (total body
fat mass - visceral mass). By clearly defining visceral vs.
non-visceral WAT, shifts in body fat distribution can
now be quantified as changes in the ratio between vis-
ceral and non-visceral fat mass. Using this definition, vis-
ceral obesity becomes the point at which the ratio of
visceral to non-visceral WAT becomes pathogenic, or
associated with disease, and the development of visceral
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portionately expand relative to non-visceral WAT.
Despite the emergent importance of accurately asses-
sing body fat distribution and understanding the etiology
of visceral obesity, the bulk of obesity-related research
remains focused on the causes and consequences of ex-
cessive body fat mass irrespective of its distribution. For
example, it is clear that positive energy balance (energy
input> energy expenditure) results in body fat gain and
that factors affecting the energy balance equation con-
tribute to the development or prevention of obesity
[45,87,88]. It is also widely accepted that a state of low-
grade systemic inflammation accompanies obesity-
related diseases though whether low-grade systemic in-
flammation is a cause or consequence of obesity-related
diseases remains unclear and highly debated [89]. In
spite of the wealth of knowledge regarding the causes
and consequences of general obesity, however, very little
is currently understood about the mechanisms control-
ling the regional storage of excess energy or the func-
tions cytokines serve in healthy, non-obese WAT. The
subsequent sections of this review therefore present evi-
dence in support of the novel hypothesis that the devel-
opment of visceral obesity may be due to impairments in
subcutaneous/non-visceral adipose function and that
repeated stressor exposure may exert these effects
through local, depot specific induction of cytokines.A novel mechanistic hypothesis for the
development of visceral obesity
A maladaptive shift in body fat distribution does not re-
quire fat mass gain; it can occur in the face of weight sta-
bility or even weight loss. In other words, the development
of visceral obesity can occur in one of three ways: 1) vis-
ceral fat mass expands to a greater relative extent than
non-visceral fat mass, 2) non-visceral fat mass atrophies to
a greater relative extent than visceral fat mass, or 3) a
combination of the above. Changes in body fat distribution
are consequently independent of total body fat mass and
regulated by distinct mechanisms [50].
Ironically, despite the fact that body fat distribution is
affected by both gains and/or losses in visceral and non-
visceral adiposity, mechanistic research has focused on
the pathways through which stress-induced perturba-
tions in steroid hormone production impact visceral fat
mass [6-12]. For that reason, little light has been shed
upon the potential mechanisms whereby repeated stres-
sor exposure impacts non-visceral fat mass and function.
Considering non-visceral WAT protects against visceral
obesity relative to its effectiveness as a storage depot
[26], it is essential to consider the possibility that stress-
induced visceral obesity occurs through a combination of
maladaptive visceral and non-visceral effects.Visceral obesity is marked by impaired subcutaneous
adipose tissue function
In healthy mammals, non-visceral WAT depots comprise
the majority of total body fat. Consequently, impairments
in non-visceral WAT function can significantly impact
lipid deposition in ectopic or visceral depots. In other
words, to properly act as a metabolic ‘sink’ or buffer
against excess energy storage in alternative locations, non-
visceral adipose tissue must be able to effectively uptake
circulating energy substrates, (re)synthesize, store and re-
tain triglyceride molecules, and expand in response to
positive energy balance [26]. If any of these buffering func-
tions (uptake, synthesis, storage, retention, expansion) be-
come impaired, the effectiveness of the tissue to buffer
excess energy is subsequently compromised. The potential
for deposition in the visceral depots thus increases as en-
ergy substrates are shunted to alternative storage locations.
In fact, data demonstrate that the capacity of subcutane-
ous adipose tissue to uptake energy and grow is inversely
associated with visceral obesity [90].
In healthy non-obese humans, Rebuffe-Scrive et al.
(1988) demonstrated that both fat cell size and lipopro-
tein lipase (LPL) activity (the enzyme which regulates the
uptake of lipids from the bloodstream) were higher in
femoral, non-visceral adipocytes than in abdominal adi-
pocytes [90]. They further established that the difference
in LPL activity between the abdominal and femoral
depots was lost with the development of visceral obesity,
but not with the development of non-visceral, lower
body obesity [90]. Explicitly, a maladaptive shift in body
fat distribution was marked by an increase in abdominal
adipocyte LPL activity and a decrease in LPL activity in
subcutaneous, femoral adipocytes [90]. Furthermore,
Stanhope et al. (2011) recently demonstrated that a fruc-
tose laden diet increased visceral adipose deposition due
to a dampened subcutaneous LPL response to fructose
based meals [91]. The authors hypothesized these obser-
vations were due to the fact that subcutaneous LPL acti-
vation is significantly more sensitive to insulin than
visceral LPL [92] and fructose produces a dampened in-
sulin response relative to glucose [91]. Thus, considering
the lipogenic function of LPL, these data strongly suggest
that the development of visceral obesity is directly due
to a reduction in the ability of subcutaneous adipose tis-
sue to uptake circulating lipids as determined by LPL ac-
tivity and local adipocyte insulin sensitivity. Healthy,
non-obese organisms have visceral adipose tissue that
expands predominantly via adipocyte hypertrophy - the
mature adipocytes get larger - whereas their non-visceral
and/or subcutaneous adipose tissue expands predomin-
antly via hyperplasia, or the process whereby new, ma-
ture adipocytes are formed [82,93,94]. In contrast,
viscerally obese organisms have subcutaneous depots that dis-
play dampened hyperplasia potential. A series of studies by
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that in lean individuals, lamin A and lamin C - essential pro-
teins for preadipocyte differentiation - are typically over-
expressed in the stroma-vascular cell fraction (i.e. non-
adipocyte) of subcutaneous adipose tissue relative to visceral
adipose tissue and this over-expression is lost when an individ-
ual becomes viscerally obese [95,96]. These data are high-
lighted because evidence suggests when a mature adipocyte
reaches a certain size - as determined by its location - it signals
the production of new adipocytes [97]. This process, termed
adipogenesis, is tightly regulated by numerous factors and
requires the commitment, proliferation and differentiation of
resident preadipocytes [98]. If adipogenesis is impaired within
subcutaneous adipose tissue its ability to adapt in the face of
sustained, positive energy balance diminishes. Collectively
these studies link visceral obesity to dysregulated subcutaneous
WAT function suggesting this depot may play a pivotal role in
the development of visceral obesity (Figure 1). We finish this
review with evidence supporting the hypothesis that repeated
stress-induced shifts in the cytokine milieu of non-visceral
WAT impair subcutaneous function which contributes to the
development of visceral obesity.
Stress induced IL-1β: a potential link between
stress and the development of visceral obesity
Adipose tissue is comprised of a multitude of cells such as
preadipocytes, mature adipocytes, mast cells, endothelial
cells, fibroblasts and numerous types of immune cells
[80,99]. Recent findings suggest that the cross-talk between
resident immune cells and adipocytes modulates adipocyteFigure 1 Stress-induced impairments in subcutaneous WAT function c
acute stress alters local WAT IL-1β content in a depot specific manner. This
shift in the milieu of inflammatory proteins found within subcutaneous adi
Consequently, circulating lipids are shunted towards to visceral adipose res
maladaptive shift in body fat distribution or an increase in the ratio of viscemetabolism, preadipocyte differentiation [100,101] and in-
nate immune function [13]. The link between immunity and
adipose metabolism was pioneered in the late 1980s by Bese-
dovsky and colleagues who demonstrated that cytokines
such as IL-1β were capable of inducing endocrine and meta-
bolic changes within the body [102]. More recent work
demonstrates that both preadipocytes and mature adipocytes
express innate immune receptors and respond to endotoxin
stimulation with the production of cytokines, chemokines
and adipokines [103]. Resident adipose tissue immune cells
have also been shown to act as local metabolic regulators
through the release of factors that alter adipocyte metabol-
ism and differentiation [100,104,105]. Moreover, changes in
the number and proportion of circulating lymphocytes
[106,107] coupled with a rise in systemic inflammatory mar-
kers (i.e. cytokines and acute phase proteins [66,106,107])
illustrates that the immune system actively responds to acute
stressor exposure [108]. Collectively these studies demon-
strate that the immune system and adipose metabolism
are tightly linked, each contributing to the function of the
other and that activation of the stress response serves as a
pathway whereby immune-metabolic cross-talk is initiated.
What’s more, we have recent data demonstrating that in-
flammatory proteins in WAT are directly affected by stres-
sor exposure in a depot specific manner.
Acute stressor exposure affects WAT cytokine
concentrations
Healthy, non-obese rats, exposed to an acute stressor (tail
shock) have elevated inflammatory protein concentrationsontribute to the development of visceral obesity. Exposure to
depot specific response, when repeated, may lead to a maladaptive
pose tissue such that its ability to properly function becomes impaired.
ulting in the development of visceral obesity as marked by a
ral to non-visceral fat mass.
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(IL-1β), tumor necrosis factor-alpha (TNF-α), and
interleukin-1 receptor antagonist (IL-1RA). Importantly
only the IL-1β protein was affected in a depot selective
fashion. More explicitly, stressor exposure increased IL-1β
5-fold in subcutaneous but not visceral WAT (Figure 2).
We have therefore chosen to focus on IL-1β as a potential
link between repeated stress and the development of vis-
ceral obesity. Within this framework, the data presented in
Figure 2 lead to two important questions: 1) what is the
functional significance of a regionally specific increase in
subcutaneous IL-1β following acute stressor exposure and
2) how might repeated activation of this response play a
role in the development of visceral obesity? Whereas the
acute activation of this response likely serves beneficial
functions, we hypothesize that repeated induction of this
depot specific response may dampen the ability of non-
visceral adipose tissue to absorb, retain lipids and/or ex-
pand via hyperplasia. Consequently visceral adipose depos-
ition is increased, thus yielding potential mechanisms
whereby stress-induced IL-1β signaling may affect body fat
distribution. These hypotheses are further discussed in the
final sections of this review.Figure 2 IL-1β response to acute stressor exposure in visceral
and subcutaneous WAT. Effect of acute stressor exposure on the
IL-1β protein content of visceral (omental) and subcutaneous
(inguinal) WAT in healthy, non-obese rats. 21 week old male F344
rats were exposed to 50 inescapable 1.5 mA tail shocks (stress,
n = 24) or remained in their home cages (no stress, n = 26). Rats were
sacrificed immediately following stressor exposure. Approximately
0.3 g of omental and subcutaneous WAT depots were harvested,
spot frozen in liquid nitrogen and processed via homogenization in
a RIPA lysis buffer. IL-1β protein analysis (pg IL-1β per mg total WAT
protein) was done via ELISA (R&D Systems Minneapolis, MN). Effect
of depot on IL-1β concentration F(1,46) = 15.751, **P< 0.001. Effect
of stress on IL-1β content: F(1,46) = 28.461, ***P< 0.0001. Depot by
stress interaction: F(3,44) = 13.312, ##P< 0.001. Values represent
group means + standard error of measurement. All experiment
protocols were approved by the Animal Care and Use Committee of
the University of Colorado at Boulder.Potential adaptive functions of the acute IL-1β stress
response in non-visceral adipose tissue
Elevations of inflammatory proteins in response to acute
stressor exposure is part of the adaptive stress response
and likely functions both locally (i.e. within tissues and
organs) and systemically [109]. Cytokines such as IL-1β
are best known for their role as immune modulators but
they also affect local tissue functions such as adipose me-
tabolism [100,110] suggesting that an acute, stress-induced
rise in subcutaneous IL-1β content serves multiple func-
tions within WAT. Given that this stress-induced IL-1β re-
sponse occurs in the absence of a pathogen and in the
WAT of healthy, non-obese rats, this cytokine may serve a
non-traditional, metabolic function rather than acting as a
traditional pro-inflammatory protein.
IL-1β is synthesized as a biologically inactive pro-
protein following the activation and translocation of a
transcription factor such as nuclear factor-kappa beta
(NF-кB) [111,112]. Following activating signals that re-
main debated, pro-IL-1β is loaded onto a multi-protein
platform called an inflammasome where it is cleaved by
the IL-1β converting enzyme (caspase-1), converted into
the mature form of IL-1β and released from the cell
[112-114]. Because the cleavage of pro-IL-1β is thought
to be followed by immediate release from its cellular
source [115,116] and the ELISA kit (R&D Systems, Min-
neapolis, MN) used to quantify our preliminary data
detects the mature form of the IL-1β protein [117], it is
suggested that the measurable increase in WAT IL-1β
reflects the release of mature IL-1β into the extracellular
milieu of the tissue. In support of this theory, we have
data demonstrating that the IL-1β measured in non-
visceral WAT is not due to blood found in the tissue.
Briefly, compared to non-perfused animals, rats exposed
to tail shock and saline perfused (to remove blood from
tissues) had equal increases in IL-1β content in their
subcutaneous WAT (data not shown). Combined with
evidence that the protein does not diffuse passively
through the vascular endothelium [106,118] these data
strongly suggest that IL-1β serves an autocrine and/or
paracrine role within WAT [119]. Furthermore, since the
primary functions of WAT are to store energy and act as
an endocrine organ, stress-induced IL-1β signaling likely
affects the metabolic and/or endocrine functions of
WAT; however, because WAT also contains immune
cells, mast cells, endothelial cells, preadipocytes and
fibroblasts, IL-1β may also modulate a host of other
functions. We therefore hypothesize that the stress-
induced release of IL-1β within non-visceral WAT may
serve metabolic and/or immunological functions that act
in concert to fuel the high-energy demands of stress and
promote host survival. The following are 4 ways in which
stress-induced IL-1β could have these effects in non-
visceral WAT.
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Multiple studies demonstrate that IL-1β has stimulating
effect on lipolysis, or the liberation of free fatty acids and
glycerol from mature adipocytes [120-123]. Stress
induced free fatty acid release provides an oxidative fuel
source for potentially active muscles and glycerol as a
substrate for gluconeogenesis for the maintenance of
blood glucose. IL-1β promotes lipolysis indirectly by re-
ducing the production and/or activity of proteins that
suppress lipolysis such as the lipid droplet-associated fat
specific protein 27 (FSP27) [124] and lipoprotein lipase
[120,125,126]. Reports have also shown that IL1β is able
to induce changes in leptin secretion [127,128] which
potentiates lipolysis through its inhibitory actions on in-
sulin [129].
Potentiates stress-induced leptin release
We have preliminary data that acute stressor exposure
induces leptin release both locally and systemically as
marked by an increase in WAT and blood leptin concen-
trations (data not shown). Since leptin secreting adipo-
cytes predominantly exist in the large, non-visceral,
subcutaneous depots [130] and acute IL-1β signaling
induces leptin secretion [127,128], stress-induced IL-1β
in non-visceral WAT depots may potentiate leptin re-
lease. Leptin may subsequently act centrally to inhibit
food intake, stimulate metabolic rate, and/or peripherally
inhibit insulin action in adipocytes [129] - all of which
would be appropriate and adaptive responses to an acute
stressor. Moreover, leptin-suppressed insulin action in
adipocytes would attenuate lipogenesis and/or potentiate
lipolysis in non-visceral WAT demonstrating a potential
mechanism for the regulation of body fat distribution.
Potentiates glucocorticoid activity
Evidence also suggests that, through its stimulating effect
on the 11-beta hydroxysteroid dehydrogenase type 1
(11β-HSD1) enzyme which converts inactive glucocorti-
coids into their active form, IL-1β may indirectly in-
crease local glucocorticoid activity [131,132]. This could
consequentially serve beneficial metabolic and immuno-
logical functions in non-visceral WAT. For example,
given that subcutaneous adipose tissue has a lower dens-
ity of glucocorticoid receptors relative to visceral adipose
tissue [11,133], subcutaneous-specific increases in gluco-
corticoid activity would help negate this difference.
Metabolically this would be advantageous because gluco-
corticoids and insulin - both of which are released fol-
lowing acute stressor exposure relative to the severity of
the stressor and the palatability of the diet available to
the stressed subject [45] - are synergistic; glucocorticoids
help insulin to promote lipid uptake and storage
[134,135]. Increased depot specific/non-visceral, post-
stress lipogenesis could then protect against visceralobesity by reinstating and maintaining the mass of the
non-visceral depots. (Note: Because circulating levels of
glucose and free fatty acids are tightly regulated, stress
induced energy substrates must be removed from the
blood either via utilization or uptake and re-storage. The
term ‘post-stress lipogenesis’, therefore, refers to the
process of removing stress-induced substrates from the
blood for storage as triglycerides within WAT. Hence,
following stress, the WAT depots with the highest lipo-
genic potential will serve as the primary re-deposition
sites for unused substrates.)
Second, the presence of IL-1β in sub-dermal tissues
such as subcutaneous WAT may immunologically
“prime” the organism to effectively and efficiently com-
bat a sub-dermal infection and/or injury [30,136]. In this
case, potentiated glucocorticoid signaling in these depots
would serve to boost the anti-inflammatory effects of
glucocorticoids thus ensuring efficient regulation of
stress-induced immune responses. Briefly, IL-1β acts as a
pro-inflammatory protein by activating the transcription
factor nuclear factor-kappa beta (NF-kβ) which initiates
the synthesis of inflammatory proteins. In the case of a
non-pathogenic stressor such as tail shock, a tightly
regulated innate immune response would benefit the or-
ganism not only by conserving energy - an activated im-
mune system can be metabolically demanding [137] -
but by preserving the life and function of innate immune
cells such as neutrophils and monocytes.
Promotes lipogenesis in resident macrophage cell
membranes
IL-1β signaling may also play a critical role in the regulation
of lipogenesis in the lipid bilayer of macrophage cell mem-
branes. Im et al. (2011) demonstrated that macrophages
from mice that don’t express sterol regulatory element
binding protein-1a ((SREBP-1a) a nutrient sensing tran-
scription factor) failed to activate lipogenesis and the release
of IL-1β following a lipopolysaccharide challenge suggesting
that IL-1β plays a central role in the link between lipid me-
tabolism and the innate immune response [138].
These data also suggest that resident WAT macro-
phages are a cellular source of stress- induced IL-1β and
that the SREBP-1a transcription factor may be involved
in the sensing and transducing of the nutrient changes
associated with acute stress in the local WAT environ-
ment. Moreover, Altintas et al. (2011) recently explored
the distribution of mast cells and resident macrophages
in subcutaneous and visceral fat of mice and found that
resident macrophages were more prevalent than mast
cells in lean WAT demonstrating that healthy, non-obese
WAT does, in fact, contain resident macrophages [80].
Our lab also has data demonstrating that the highest
concentration of basal and stress-induced IL- 1β lay
within the stromal-vascular fraction of WAT (Figure 3).
Figure 3 IL-1β response to acute stressor exposure in adipocyte
and stroma-vascular fractions of subcutaneous WAT. Effect of
acute stressor exposure on the IL-1β protein content of stromal-
vascular and adipocyte fractions of subcutaneous (inguinal) WAT in
healthy, non-obese rats. 21 week old male F344 rats were exposed
to 50 inescapable 1.5 mA tail shocks (stress, n = 3) or remained in
their home cages (no stress, n = 3). Rats were sacrificed immediately
following stressor exposure. Approximately 0.3 g of subcutaneous
WAT was harvested and digested via standard WAT collagenase
digestion [139]. The stroma-vascular and adipocyte fractions were
then processed via homogenization in a RIPA lysis buffer. IL-1β
protein analysis (pg IL-1β per mg total protein) was done via ELISA
(R&D Systems Minneapolis, MN). Effect of fraction on IL-1β
concentration F(1,8) = 15.751, ***P< 0.0001. Effect of stress on IL-1β
content: F(1,8) = 7.031, *P< 0.05. Fraction by stress interaction: F
(3,6) = 15.697, ##P< 0.01. Values represent group means + standard
error of measurement. All experiment protocols were approved by
the Animal Care and Use Committee of the University of Colorado at
Boulder.
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phages per se are the cellular source of stress-induced
IL- 1β. More work is necessary to determine the precise
cellular sources of stress-induced IL-1β as other cells
found in the stromal-vascular fraction of WAT likely
contribute to the stress-induced IL-1β pool.
In summary, following acute stressor exposure, depot
specific induction of IL-1β release may serve adaptive
functions including potentiated lipolysis, leptin release
and glucocorticoid activity. While a short-lived rise in
subcutaneous WAT IL-1β is likely beneficial in nature,
we propose the opposite holds true when repeatedly
induced [105,109]. Hence the final section of this review
presents evidence suggesting that repeated exposure to
IL-1β in subcutaneous WAT may elicit maladaptive
effects that could collectively contribute to the develop-
ment of visceral obesity.
Potential IL-1β related mechanisms whereby repeated
stressor exposure induces a maladaptive shift in body fat
distribution
Lipogenesis, or the process of removing energy sub-
strates from the bloodstream and synthesizing them into
a triglyceride molecule (i.e. three free fatty acids attachedto a glycerol backbone), is the foundation upon which
WAT stores and retains energy. The process of cleaving
triglyceride molecules and liberating them as free fatty
acids for energy utilization is termed lipolysis. The bal-
ance between these two processes, or lipolytic flux,
determines the mean size of the mature adipocytes
within the depot [76].
The protective nature and function of non-visceral adi-
pose tissue is associated with its ability to uptake circu-
lating energy substrate, synthesize and/or retain
triglyceride [26] and to expand via hyperplasia during
prolonged positive energy balance [139]. Conversely, the
pathogenic nature of visceral adipose is related to its
ability to expand via hypertrophy and/or hyperplasia.
Dysfunction of WAT therefore implies that its lipogenic
and/or adipogenic abilities become maladaptive relative
to its location. Interestingly, recent data demonstrate
that the local milieu of inflammatory proteins modulates
lipid uptake and release [100] suggesting that inflamma-
tory proteins such as IL-1β may impact body fat distribu-
tion through the sum of their local effects on adipose
metabolism. Evidence also demonstrates that viscerally
obese subjects have subcutaneous adipose tissue that is
marked by decreased expression of lipogenic and adipo-
genic proteins [26,140-143]. In spite of this evidence, no
clear mechanisms have been proposed to date for the
means whereby these impairments occur. While it is
possible that repeated stressor exposure may drive vis-
ceral fat expansion by increasing the capability of visceral
WAT to expand via hypertrophy and/or hyperplasia, we
pose that repeated stress-induced IL-1β signaling nega-
tively affects subcutaneous adipose tissue by dampening
its lipogenic and/or adipogenic function. We offer evi-
dence for the following hypothetical mechanisms, each
of which, through their negative affect on subcutaneous
WAT function, could contribute to the development of
visceral obesity (Figure 4). Notably, repeated stressor ex-
posure also induces variations in glucose-homeostasis
[144], however, further discussion on this topic is beyond
the scope of this review.
Impaired lipogenesis
The capacity of adipose tissue to absorb circulating lipids
is regulated by the local expression and activity of LPL
[145]. Because LPL activity is known to vary between
adipose depots, it is thought to play a major role in regu-
lating the distribution of fat deposition [29]. As Rebuffe-
Scrive et al. (1988) and Stanhope et al. (2011) have
described, the development of visceral obesity is marked
by a decrease in LPL activity in subcutaneous adipose
tissue [90]. Interestingly, separate studies demonstrate
not only that IL-1β signaling directly decreases the activ-
ity of the LPL enzyme [120,122,146] but that repeated




























Figure 4 Repeated stress-induced IL-1β may contribute to the development of visceral obesity through impairments in non-visceral
WAT function. Repeated exposure to acute stress may induce a maladaptive shift in the inflammatory milieu of subcutaneous adipose tissue marked
by a repeated, regionally specific rise in IL-1β. In turn, this may lead to subcutaneous dysfunction or impairments in the depots’ ability to 1) uptake
lipids, 2) resynthesize and/or retain lipids, and 3) expand via hyperplasia in the face of positive energy balance. These IL-1β-induced WAT dysfunctions
may occur through the following mechanisms: 1) reduced lipoprotein lipase (LPL) activity - a decrease in LPL activity reduces lipid uptake which
reduces triglyceride re-synthesis and storage and increases circulating lipid concentrations; 2) reduced Lipin-1 expression - decreased Lipin-1 expression
negatively affects triglyceride re-synthesis and storage which further increases net circulating lipid concentrations; 3) reduced adipogeneic potential.
IL-1β signaling activates the transcription factor NF-kβ which then reduces PPARγ activity. A reduction in PPARγ impairs adiopgenesis, or the
differentiation of preadipocytes into mature, lipid storing, adipocytes. Collectively these effects may contribute toward the development of visceral
obesity by a) reducing the size of non-visceral adipose depots relative to visceral adipose due to an imbalance in lipolytic flux (lipolysis> lipogenesis)
and/or b) by shunting circulating lipids to non-visceral WAT for deposition due to the increased concentration of circulating lipids and reduced
lipogenic/adipogenic potential of non-visceral WAT. Abbreviations: TG - triglyceride; FFA - free fatty acid; LPL - lipoprotein lipase; ACS - AcylCoA
synthase; GK- glycerol kinase; NFkβ- nuclear factor kappa beta; PPARγ - peroxisome proliferator-activated receptor gamma.
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tivity is largely under the control of insulin demonstrat-
ing that IL-1β can directly and indirectly affect the
activity of LPL [144,149]. IL-1β is also known to induce
leptin secretion which further reduces insulin signaling
in adipocytes. The decrease in lipoprotein lipase activity
found in the subcutaneous adipose of viscerally obese
subjects may be therefore be due to impaired insulin sig-
naling induced by repeated IL-1β signaling in chronically
stressed, subcutaneous adipose tissue. It is important to
state, however, that IL-1β’s effects on insulin signaling
and leptin secretion appear to be time-dependent; an
acute rise in IL-1β has little to no effect on insulin sensi-
tivity and potentiates leptin secretion whereas repeated
or sustained exposure to the cytokine impairs insulin sig-
naling and leptin secretion [121,127,146,147,150]. These
data highlight the significance of short-term versus
repeated or sustained IL-1β signaling and illustrate its
potentially maladaptive effect on adipocyte function.
Mature adipocyte as well as lipid droplet size - adipocyte
size is directly correlated to the size of its lipid droplets[151] - have also been shown to modulate local adipose me-
tabolism. Ranjit et al. (2011) recently demonstrated that the
lipolytic action of IL-1β is accompanied by a marked de-
crease in lipid droplet size and the expression of lipid
droplet-associated fat specific protein 27 (FSP27 - a lipolytic
suppressor) in mouse adipocytes [124]. On the other hand,
Boivin et al. (2007) examined adipocytes from omental and
subcutaneous WAT of 33 men ranging in BMI from 24.6 to
79.1 kg/m2 and found no differences in basal or iso-
proterenol induced lipolysis values between the depots
across waist circumference tertiles [152]. The authors
speculate, however, that this could be partly explained by
the fact that differences in adipocyte size are important
determinants of regional differences in adipose metabolism
and their subject’s adipocytes were similar in size both be-
tween depots and across waist circumference [152]. Thus,
through its potential effect on lipid droplet size, these data
substantiate the hypothesis that IL-1β may play a role in the
regulation of regionally-specific lipolytic responses to stress.
Evidence also suggests that IL-1β may dampen the
ability of an adipocyte to resynthesize triglyceride
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on the regulation of Lipin-1 expression and activity - an
essential enzyme for triglyceride synthesis - and found
that the expression of Lipin-1 was suppressed by IL-1β
in cultured 3T3-L1 adipocytes and in mouse adipose tis-
sue [123]. These data therefore suggest that repeated
depot specific IL-1β signaling could contribute to a re-
duction in triglyceride synthesis thus reducing its buffer-
ing capacity while promoting the release of free fatty
acids into the circulation.
Finally, in the case of sustained IL-1β and glucocortic-
oid signaling - the consequence of which is dampened
insulin signaling - the acute benefit of site-specific post-
stress lipogenesis becomes lost. In other words, if
repeated stressor exposure reduces the buffering capacity
of the non-visceral depots by impairing insulin signaling,
LPL activity, and Lipin-1 expression it follows that a con-
sequential increase in visceral and/or ectopic fat depos-
ition would occur.
Impaired lipid retention
While acute mobilization of fatty acids from WAT is
adaptive for energy mobilization during acute stress, if
lipolysis is not equally opposed by post-stress lipogenesis,
dissolution of the depot occurs. Lipid re-synthesis and
retention in non-visceral WAT, therefore, is essential for
the prevention visceral obesity. The ability of subcutane-
ous adipose tissue to retain lipids depends on the degree
to which it is signaled to undergo lipolysis. As presented
earlier, evidence suggests that IL-1β may both directly
[83-85] and indirectly promote lipolysis. When un-
matched by lipogenesis due to a decrease in LPL activity,
insulin signaling, or Lipin-1 activity, atrophy of the sub-
cutaneous depot occurs. These data therefore suggest
that stress-induced IL-1β may lead to the development
of visceral obesity by impeding the ability of subcutane-
ous adipose tissue to effectively uptake energy substrate
and to re-synthesize and retain triglyceride molecules.
Impaired adipogenesis
Expansion of a WAT depot occurs through hypertrophy
of mature adipocytes and/or through hyperplasia. The
creation of new, mature adipocytes, or adipogenesis,
involves the replication and differentiation of preadipo-
cyte cells into mature, lipid storing adipoctyes and recent
data demonstrate that the degree to which mature adipo-
cytes can be formed depends upon the phenotype of the
preadipocyte found within the depot [79,153]. Isakson
et al. (2009) have further established that the phenotype
of resident preadipocytes can be changed based on the
composition of the inflammatory proteins found in the
depot [142]. Moreover, whereas healthy, non-obese
omental WAT contains preadipocytes with a reduced
capacity for replication and differentiation [79], thepreferred modality for healthy subcutaneous WAT ex-
pansion is through adipogenesis [82,94,154]. Because
non-visceral depots constitute the bulk of total body fat
mass, it therefore follows that a diminutive reduction in
the adipogenic potential of subcutaneous WAT would
negatively affect body fat distribution [82,93,94,139]. In
support of our hypothesis that IL-1β could dampen the
adipogenic potential of subcutaneous WAT, Lu et al.
(2010) reported that the presence of as little as 5.0 pg/
mL of IL-1β (equivalent to basal concentrations in vis-
ceral rat WAT) in the culture medium of 3T3-L1 preadi-
pocytes inhibited adipogenesis [155]. Lu et al. (2010)
further demonstrated that preadipocyte differentiation
was also impaired upstream of IL-1β at the level of NF-
кB due to its effect on the adipogenic transcription fac-
tor, PPARγ [155]. These data support other studies in
which a rise in NF-κB activity leads to a reduction in
PPARγ expression/activity and impairments in adipogen-
esis [156,157]. In this manner stress-induced IL-1β sig-
naling could drive ectopic lipid deposition and visceral
fat expansion by reducing the adipogenic potential of
subcutaneous WAT. Contrary to this postulation, how-
ever, are data from Weise et al. (2008) suggesting that
IL-1β stimulates the expression of tissue inhibitor of
metalloproteinase (TIMP)-1, a protein thought to pro-
mote preadipocyte differentiation [158] and shown to be
elevated in the serum of viscerally obese subjects [159].
Though Weise et al. (2008) demonstrated increased
TIMP-1 secretion from mature 3T3-L1 adipocyte cells,
concentrations of 0.5-20.0 ng/mL of IL-1β were required
to induce this response [160] which may be outside of
the physiological range for WAT. For example, as shown
in Figure 2, stressed subcutaneous WAT concentrations
rose to only 0.02 ng/mg total tissue. In addition, Weise
et al. (2008) failed to demonstrate that IL-1β induced
TIMP-1 synthesis leads to an increase in preadipocyte
differentiation [160]. Consequently, the physiological
relevance of their in vivo data in this study is unclear.
Finally, because glucocorticoid activation and signaling
is known to stimulate early preadipocyte differentiation
[161], an IL-1β induced rise in glucocorticoid activity
seemingly contradicts the hypothesis that repeated ex-
posure to IL-1β impairs the adiopogenic potential of adi-
pose tissue. Interestingly, however, a transgenic study
done by Masuzaki et al. (2001) demonstrated that depot
specific increases in 11β-HSD1 activity did not, in fact,
stimulate the differentiation of preadipocytes in either
subcutaneous or visceral adipose tissue [12]. Instead,
gains in adiposity instigated through transgenic over-
expression of the enzyme were predominantly due to
hypertrophy of the visceral adipocytes [12] suggesting
that the effects of this enzyme are site dependent. While
the authors speculated that exaggerated visceral fat de-
position was due to enhanced glucocorticoid receptor
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hyperplasia found in the depots [12]. Although inflam-
matory proteins were not assessed in this study, our data
along with the aforementioned studies [155,156] suggest
that a rise in IL-1β activity and/or the activity of its pri-
mary transcription factor NF-кB may be involved in
modulating the site specific effects of 11β-HSD1 and/or
glucocorticoids on preadipocyte differentiation and adi-
pocyte metabolism.
Despite conflicting evidence it is clear that sustained
impairment of subcutaneous expansion or an increase in
the capacity of visceral preadipocytes to expand or repli-
cate in the face of positive energy balance could have
momentous consequences on body fat distribution. As to
which of these maladaptive events occurs first and
where, though, remains unclear. Current data demon-
strate that the inherent differences among the pheno-
types of cells found within WAT depots contribute
toward the interdepot variations seen in response to in-
trinsic and extrinsic stimuli such as IL-1β. Future re-
search must therefore aim to understand the unique and
adaptive functions of WAT and WAT proteins relative to
time and depot location.
Conclusions
In closing, stressors are an unavoidable fact of life for
every organism. Our apparent inability to adaptively
minimize and cope with stressors, coupled with a highly
palatable/contemporary diet, has contributed to the de-
velopment of a viscerally obese population [162]. While
there is substantial evidence to support the idea that
chronic stress is associated with disproportionate gains
in visceral adiposity, the mechanisms whereby this se-
lective deposition pattern occurs remain unclear. What
is more, many of the studies that have investigated the
potential effects of chronic stressor exposure on visceral
obesity have failed to accurately assess body fat distribu-
tion, making an accurate characterization of its effects
difficult to decipher.
Recent evidence suggests that local inflammatory pro-
teins modulate adipocyte function and may therefore
play a role in the regulation of body fat distribution. We
present new data that acute stressor exposure increases
the concentration of mature IL-1β within subcutaneous
white adipose tissue to a significantly greater extent than
in visceral white adipose tissue of healthy, non-obese
rats. Acutely, the rise in this inflammatory protein likely
serves beneficial functions such as increased lipolysis,
increased leptin secretion and potentiated glucocorticoid
signaling. However, if IL-1β signaling is sustained
through repeated stressor exposure it could contribute to
gains in visceral fat mass by reducing the ability of the
subcutaneous adipose tissue to uptake, synthesize and
retain triglyceride, and/or expand via hyperplasia in theface of positive energy balance. Further exploration of
these novel hypotheses promises to expand our under-
standing of the adaptive functions of inflammatory pro-
teins in healthy, non-obese adipose tissue and the
mechanisms through which subcutaneous adipose tissue
function may contribute to the regulation of body fat
distribution and the development of visceral obesity. If
local cross-talk between the innate and metabolic sys-
tems contributes to the development of visceral obesity,
understanding the mechanisms whereby this occurs
could lead to the development of therapeutic targets for
the prevention of visceral obesity, the metabolic syn-
drome, and its associated diseases.
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